Switching from Apixaban to Enoxaparin for NPO Patients

Rationale for Switching to Parenteral Anticoagulation

The American College of Cardiology recommends parenteral anticoagulation for patients who cannot take oral medications, such as those on NPO status, with apixaban having a half-life of approximately 12 hours 1
When patients are placed on NPO status, oral medications including direct oral anticoagulants (DOACs) like apixaban cannot be administered, necessitating alternative routes of anticoagulation, such as enoxaparin 2
Guidelines specifically recommend considering parenteral anticoagulation for patients who are NPO or awaiting invasive procedures, with the American College of Cardiology providing guidance on this topic 1

For patients with normal renal function, enoxaparin can be started 12-24 hours after the last dose of apixaban, considering the half-life of apixaban 3
Enoxaparin dosing is as follows: for younger patients <75 years, 1 mg/kg SC every 12 hours; for patients ≥75 years, 0.75 mg/kg SC every 12 hours without an initial IV bolus; and for patients with impaired renal function, 1 mg/kg SC once daily or consider unfractionated heparin instead, according to the American Heart Association guidelines 4

Patients initially treated with apixaban should not be abruptly switched to heparin and vice versa because of increased risk of bleeding, as recommended by the American College of Cardiology 4
For patients with high thrombotic risk, ensure minimal gap in anticoagulation coverage during the transition, with the American College of Cardiology providing guidance on this topic 3

Monitor for signs of bleeding during the transition period, with the American College of Cardiology recommending close monitoring 1
For patients with renal impairment, closer monitoring may be necessary as both drugs are affected by kidney function, according to the American Heart Association guidelines 4

Avoid switching between different anticoagulants unnecessarily as this may increase bleeding risk, as recommended by the American Heart Association 4
Be aware that enoxaparin requires dose adjustment in renal impairment, which is different from apixaban dose adjustments, with the American College of Cardiology providing guidance on this topic 4

In patients with atrial fibrillation who are on apixaban for stroke prevention and become temporarily unable to take oral medications (e.g., NPO status), the standard switching protocol to parenteral anticoagulation (such as enoxaparin) should be followed; aspirin monotherapy is advised only for patients with permanent contraindications to oral anticoagulants, not for short‑term NPO situations. 5